Editas Medicine (EDIT) Receivables (2015 - 2025)
Editas Medicine (EDIT) reported Receivables of $15.2 million for Q4 2025, down 6.7% year-over-year from $16.3 million in Q4 2024, and up 86.67% quarter-over-quarter from $8.1 million in Q3 2025.
Editas Medicine (EDIT) Receivables (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 11 years of Receivables data on file, last reported at $15.2 million in Q4 2025.
- Receivables for Q4 2025 came in at $15.2 million, down 6.7% year-over-year; the trailing twelve-month figure through Dec 2025 was $15.2 million (down 6.7% YoY), and the FY2025 annual result was $15.2 million, down 6.7% from the prior year.
- Receivables grew to $15.2 million in Q4 2025 per EDIT's latest filing, from $8.1 million in the prior quarter.
- Over five years, Receivables peaked at $16.3 million in Q4 2024 and troughed at $120000.0 in Q3 2022.
- A 5-year average of $3.3 million and a median of $630000.0 in 2021 frame the typical range for Receivables.
- The sharpest annual moves came in 2021 and 2025: Receivables sank 95.59% in 2021, then surged 6352.38% in 2025.
- A 5-year view of Receivables shows it stood at $267000.0 in 2021, then soared by 1826.97% to $5.1 million in 2022, then jumped by 98.0% to $10.2 million in 2023, then surged by 59.67% to $16.3 million in 2024, then declined by 6.7% to $15.2 million in 2025.
- Business Quant data shows EDIT's Receivables at $15.2 million in Q4 2025, $8.1 million in Q3 2025, and $588000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Editas Medicine | 262.77 Mn | 262.77 Mn | - | 15.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.18 Mn |
| Sep 30, 2025 | 8.13 Mn |
| Jun 30, 2025 | 588,000.00 |
| Mar 31, 2025 | 510,000.00 |
| Dec 31, 2024 | 16.27 Mn |
| Sep 30, 2024 | 126,000.00 |
| Jun 30, 2024 | 244,000.00 |
| Mar 31, 2024 | 245,000.00 |
| Dec 31, 2023 | 10.19 Mn |
| Sep 30, 2023 | 2.42 Mn |
| Jun 30, 2023 | 2.29 Mn |
| Mar 31, 2023 | 242,000.00 |
| Dec 31, 2022 | 5.15 Mn |
| Sep 30, 2022 | 120,000.00 |
| Jun 30, 2022 | 713,000.00 |
| Mar 31, 2022 | 1.37 Mn |
| Dec 31, 2021 | 267,000.00 |
| Sep 30, 2021 | 251,000.00 |
| Jun 30, 2021 | 331,000.00 |
| Mar 31, 2021 | 672,000.00 |